Answers are grounded in this paper and cite their sources.
Narrative review examines adoptive T cell therapy for cancer, highlighting engineered cellular approaches and host microenvironment modulation to overcome hurdles in clinical translation.
The transfusion of T cells, also called adoptive T cell therapy, is an effective treatment for viral infections and has induced regression of cancer in early-stage clinical trials. However, recent advances in cellular immunology and tumor biology are guiding new approaches to adoptive T cell therapy. For example, use of engineered T cells is being tested as a strategy to improve the functions of effector and memory T cells, and manipulation of the host to overcome immunotoxic effects in the tumor microenvironment has led to promising results in early-stage clinical trials. Challenges that face the field and must be addressed before adoptive T cell therapy can be translated into routine clinical practice are discussed.
No takes yet. Share an insight, caveat, or question.
Carl H. June (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: